Statins and hypertension

Seminars in Vascular Medicine

Volumn 4, Issue 4, 2004, Pages 367-375

  Pelat, Michel ^a   Balligand, J L ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Blood pressure variability; Caveolin; Endothelium; Hypertension; Nitric oxide synthase; Statins

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CHOLESTEROL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NITRENDIPINE; NORADRENALIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; HEART RATE VARIABILITY; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; PLEIOTROPY; REVIEW; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; LIPIDS; RISK FACTORS;

EID: 17744376165     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-869593     Document Type: Review

References (62)

1. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
2. Lloyd-Jones DM, Evans JC, Larson MG, et al. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. Arch Intern Med 1999;159:2206-2212
3. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467
4. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:897-905
5. Fielding CJ, Bist A, Fielding PE. Caveolin mRNA levels are up-regulated by free cholesterol and down-regulated by oxysterols in fibroblast monolayers. Proc Natl Acad Sci USA 1997;94:3753-3758
6. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 1997;272:H2701-H2707
7. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999;99:2027-2033
8. Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes 2001;109:S533-S547
9. Bakker SJ, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis 2000;148:17-21
10. Igarashi K, Tsuji M, Nishimura M, et al. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apheresis 2004;19:11-16
11. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95:76-82
12. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004;6:27-35
13. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension 1998;31:225-231
14. Jiang J, Sun CW, Alonso-Galicia M, et al. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Am J Hypertens 1998;11:1222-1231
15. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997;30:968-974
16. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003;42:1091-1097
17. Straznicky NE, Howes LG, Lam W, et al. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75:582-586
18. Abetel G, Poget PN, Bonnabry JP. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med Wochenschr 1998;128:272-277
19. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-1286
20. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-1499
21. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35:549-555
22. Nazzaro P, Manzari M, Merlo M, et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999;33:719-725
23. Leibovitz E, Hazanov N, Zimlichman R, et al. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001;14:1096-1098
24. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-987
25. Prasad GV, Ahmed A, Nash MM, et al. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003;63:360-364
26. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540-556
27. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-2719
28. Hernandez-Perera O, Perez-Sala D, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000;87:616-622
29. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:1896-1901
30. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001;59:646-654
31. Wassmann S, Hilgers S, Laufs U, et al. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-1212
32. Delbosc S, Morena M, Djouad F, et al. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002;40:611-617
33. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135
34. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271
35. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010
36. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113-118
37. Pelat M, Dessy C, Massion P, et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003;107:2480-2486
38. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449-2452
39. Frank PG, Lee H, Park DS, et al. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:98-105
40. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982-985
41. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-1437
42. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002;40:868-874
43. Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19:22-27
44. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39:1020-1025
45. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-2060
46. Raison J, Rudnichi A, Safar ME. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J Hum Hypertens 2002;16:705-710
47. Youssef F, Seifalian AM, Jagroop IA, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002;23:358-364
48. Parati G, Pomidossi G, Albini F, et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987;5:93-98
49. Frattola A, Parati G, Cuspidi C, et al. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993;11:1133-1137
50. Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001;19:1981-1989
51. Sander D, Kukla C, Klingelhofer J, et al. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000;102:1536-1541
52. Parati G, Bilo G, Vettorello M, et al. Assessment of overall blood pressure variability and its different components. Blood Press Monit 2003;8:155-159
53. Mussalo H, Vanninen E, Ikaheimo R, et al. Short-term blood pressure variability in renovascular hypertension and in severe and mild essential hypertension. Clin Sci (Lond) 2003;105:609-614
54. Frattola A, Parati G, Castiglioni P, et al. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension 2000;36:622-628
55. Liu JG Xu LP, Chu ZX, et al. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003;21:1961-1967
56. Stauss HM, Nafz B, Mrowka R, et al. Blood pressure control in eNOS knock-out mice: comparison with other species under NO blockade. Acta Physiol Scand 2000;168:155-160
57. Riahi S, Christensen JH, Toft E, et al. HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 2002;45:479-483
58. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-648
59. Pehlivanidis AN, Athyros VG, Demitriadis DS, et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001;157:463-469
60. Welzig CM, Shin DG, Park HJ, et al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation 2003;108:2743-2746
61. Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95:700-704
62. Pliquett RU, Cornish KG, Peuler JD, et al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107:2493-2498